The phenomenon of taking five or more medicines at the same time has become so common that it now has its own term – polypharmacy – and there is no doubt that it increases the risk of dizziness, confusion, and loss of balance.
Since its inception, AI in prior auth has only been at work in the commercial healthcare marketplace. Now new innovative approaches that reframe prior auth as a resource instead of a roadblock have come to Medicare via the WISeR model.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Sixty million rural Americans aren’t asking for another strategic framework. They’re asking for care — accessible, affordable, and delivered with dignity.
With science funding catapulted into the cultural conversation more than ever in the last year, it faces a critical inflection point. There is an opportunity to design a path forward that builds stability in the short term and opens doors in the long term for foundational and transformational science and technology solutions that will benefit our planet and its people.
At the heart of this fight are the patients whose lives quite literally depend on Medicaid. But we are also fighting for the caregivers who show up every day, the children who rely on stability, the families who rally around their loved ones, and all those whose lives are shaped by access to care.
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
The technologies and techniques developed for eye transplantation and nerve regeneration may have significant translational potential for other biomedical needs including: spinal cord injury, central nervous system regeneration, retinal cell and tissue transplantation, and other forms of organ and tissue transplantation.
The Supreme Court upheld the Affordable Care Act, dismissing the lawsuit brought by Texas, 17 other states and two individuals on the grounds that they were not able to prove they were harmed by the law. Industry stakeholders celebrated the court's long-awaited decision.
A group of biotech executives, entrepreneurs, academics and researchers has sent an open letter to President Trump arguing that if DACA is not preserved, the economy (and by association the biotech industry) stands to lose and bigly.